Teprotumumab in Clinical Practice: Recommendations and Considerations From the OPTIC Trial Investigators

Thyroid eye disease (TED) is a vision-threatening and debilitating condition that until very recently had no Food and Drug Administration (FDA)-approved medical therapies. Teprotumumab has recently been approved to treat TED. We aim to provide guidance for its use, based on the input of the US inves...

Descripción completa

Detalles Bibliográficos
Autores principales: Douglas, Raymond S., Wang, Yao, Dailey, Roger A., Harris, Gerald J., Wester, Sara T., Schiffman, Jade S., Tang, Rosa A., Fowler, Brian, Fleming, James, Smith, Terry J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Journal of Neuro-Ophthalmology 2021
Materias:
Original Contribution
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8584196/
https://www.ncbi.nlm.nih.gov/pubmed/33417417
http://dx.doi.org/10.1097/WNO.0000000000001134

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8584196/
https://www.ncbi.nlm.nih.gov/pubmed/33417417
http://dx.doi.org/10.1097/WNO.0000000000001134

Ejemplares similares